US5296236A
(en)
*
|
1988-09-16 |
1994-03-22 |
Recordati S.A., Chemical And Pharmaceutical Company |
Controlled release therapeutic system for a liquid pharmaceutical formulations
|
DK0418565T3
(da)
*
|
1989-09-21 |
1995-01-23 |
American Cyanamid Co |
Pulserende system til afgivelse af minocyclin en gang dagligt
|
US6764697B1
(en)
*
|
1991-06-27 |
2004-07-20 |
Alza Corporation |
System for delaying drug delivery up to seven hours
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
IT1252185B
(it)
*
|
1991-12-11 |
1995-06-05 |
Therapicon Srl |
Preparazioni farmaceutiche a liberazione programmata
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5472712A
(en)
*
|
1991-12-24 |
1995-12-05 |
Euroceltique, S.A. |
Controlled-release formulations coated with aqueous dispersions of ethylcellulose
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
ES2115638T3
(es)
*
|
1991-12-30 |
1998-07-01 |
Akzo Nobel Nv |
Composicion tiroactiva de liberacion controlada.
|
US7070806B2
(en)
*
|
1992-01-27 |
2006-07-04 |
Purdue Pharma Lp |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5262173A
(en)
*
|
1992-03-02 |
1993-11-16 |
American Cyanamid Company |
Pulsatile once-a-day delivery systems for minocycline
|
WO1993017673A1
(en)
*
|
1992-03-03 |
1993-09-16 |
Top Gold Pty., Limited |
Sustained release analgesics
|
ZA933725B
(en)
*
|
1992-05-28 |
1993-12-15 |
Elan Corp Plc |
Tablet formulation
|
WO1994003421A2
(en)
*
|
1992-07-30 |
1994-02-17 |
Cal International Limited |
Esters and combinations of an organic nitrate and a salicylate
|
US5422122A
(en)
*
|
1992-08-04 |
1995-06-06 |
Eurand America, Incorporated |
Controlled release potassium chloride tablet
|
US5376384A
(en)
*
|
1992-12-23 |
1994-12-27 |
Kinaform Technology, Inc. |
Delayed, sustained-release pharmaceutical preparation
|
USRE39300E1
(en)
|
1993-01-28 |
2006-09-19 |
Virginia Commonwealth University Medical College Of Virginia |
Inhibiting the development of tolerance to and/or dependence on an addictive substance
|
US5321012A
(en)
*
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
NZ260408A
(en)
*
|
1993-05-10 |
1996-05-28 |
Euro Celtique Sa |
Controlled release preparation comprising tramadol
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
WO1995003052A1
(en)
*
|
1993-07-22 |
1995-02-02 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
US5662933A
(en)
*
|
1993-09-09 |
1997-09-02 |
Edward Mendell Co., Inc. |
Controlled release formulation (albuterol)
|
US5455046A
(en)
*
|
1993-09-09 |
1995-10-03 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US5773025A
(en)
*
|
1993-09-09 |
1998-06-30 |
Edward Mendell Co., Inc. |
Sustained release heterodisperse hydrogel systems--amorphous drugs
|
US6726930B1
(en)
*
|
1993-09-09 |
2004-04-27 |
Penwest Pharmaceuticals Co. |
Sustained release heterodisperse hydrogel systems for insoluble drugs
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US5484607A
(en)
*
|
1993-10-13 |
1996-01-16 |
Horacek; H. Joseph |
Extended release clonidine formulation
|
US6210714B1
(en)
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5500227A
(en)
*
|
1993-11-23 |
1996-03-19 |
Euro-Celtique, S.A. |
Immediate release tablet cores of insoluble drugs having sustained-release coating
|
US5419917A
(en)
*
|
1994-02-14 |
1995-05-30 |
Andrx Pharmaceuticals, Inc. |
Controlled release hydrogel formulation
|
JP2716361B2
(ja)
*
|
1994-02-16 |
1998-02-18 |
株式会社アドバンス |
生体用プリント電極
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
US5411745A
(en)
*
|
1994-05-25 |
1995-05-02 |
Euro-Celtique, S.A. |
Powder-layered morphine sulfate formulations
|
US6077533A
(en)
*
|
1994-05-25 |
2000-06-20 |
Purdue Pharma L.P. |
Powder-layered oral dosage forms
|
US7060293B1
(en)
|
1994-05-25 |
2006-06-13 |
Purdue Pharma |
Powder-layered oral dosage forms
|
GB9422154D0
(en)
*
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5834024A
(en)
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
GB9503492D0
(en)
*
|
1995-02-22 |
1995-04-12 |
Ed Geistlich S Hne A G F R Che |
Chemical product
|
US20030109503A1
(en)
*
|
1995-06-06 |
2003-06-12 |
Smithkline Beecham P.L.C. |
Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
|
AU6122496A
(en)
*
|
1995-06-20 |
1997-01-22 |
Pharma-Vinci A/S |
A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
ATE261303T1
(de)
|
1995-09-21 |
2004-03-15 |
Pharma Pass Ii Llc |
Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US5840332A
(en)
*
|
1996-01-18 |
1998-11-24 |
Perio Products Ltd. |
Gastrointestinal drug delivery system
|
US5773031A
(en)
*
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
US20060068002A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
WO1998001117A1
(en)
|
1996-07-08 |
1998-01-15 |
Edward Mendell Co., Inc. |
Sustained release matrix for high-dose insoluble drugs
|
IT1283478B1
(it)
*
|
1996-07-22 |
1998-04-21 |
Roberto Valducci |
Composizioni per integrazione nutrizionale comprendenti vitamine idrosolubili a rilascio prolungato
|
HRP970493A2
(en)
*
|
1996-09-23 |
1998-08-31 |
Wienman E. Phlips |
Oral delayed immediate release medical formulation and method for preparing the same
|
WO1998029095A2
(en)
*
|
1997-01-03 |
1998-07-09 |
Elan Corporation, Plc |
Sustained release cisapride mini-tablet formulation
|
US5891474A
(en)
*
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US5788987A
(en)
*
|
1997-01-29 |
1998-08-04 |
Poli Industria Chimica Spa |
Methods for treating early morning pathologies
|
US20030124187A1
(en)
*
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
FR2760190B1
(fr)
*
|
1997-02-28 |
1999-04-09 |
Adir |
Composition pharmaceutique pour la liberation programmee de dexfenfluramine
|
US5840329A
(en)
*
|
1997-05-15 |
1998-11-24 |
Bioadvances Llc |
Pulsatile drug delivery system
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
WO1999001111A1
(en)
|
1997-07-02 |
1999-01-14 |
Euro-Celtique, S.A. |
Stabilized sustained release tramadol formulations
|
MY125849A
(en)
*
|
1997-07-25 |
2006-08-30 |
Alza Corp |
Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
|
US6056977A
(en)
|
1997-10-15 |
2000-05-02 |
Edward Mendell Co., Inc. |
Once-a-day controlled release sulfonylurea formulation
|
US6337091B1
(en)
|
1997-10-27 |
2002-01-08 |
Temple University - Of The Commonwealth System Of Higher Education |
Matrix for controlled delivery of highly soluble pharmaceutical agents
|
FR2774910B1
(fr)
|
1998-02-16 |
2001-09-07 |
Ethypharm Lab Prod Ethiques |
Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques
|
UA65607C2
(uk)
|
1998-03-04 |
2004-04-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Фармацевтична композиція (варіанти) та спосіб її приготування
|
US6372254B1
(en)
|
1998-04-02 |
2002-04-16 |
Impax Pharmaceuticals Inc. |
Press coated, pulsatile drug delivery system suitable for oral administration
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
US6197347B1
(en)
|
1998-06-29 |
2001-03-06 |
Andrx Pharmaceuticals, Inc. |
Oral dosage for the controlled release of analgesic
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6368625B1
(en)
|
1998-08-12 |
2002-04-09 |
Cima Labs Inc. |
Orally disintegrable tablet forming a viscous slurry
|
US6126967A
(en)
*
|
1998-09-03 |
2000-10-03 |
Ascent Pediatrics |
Extended release acetaminophen particles
|
US6254891B1
(en)
*
|
1998-09-03 |
2001-07-03 |
Ascent Pediatrics, Inc. |
Extended release acetaminophen
|
JP2000109341A
(ja)
|
1998-10-01 |
2000-04-18 |
Jsr Corp |
無機粒子含有組成物、転写フィルムおよびプラズマディスプレイパネルの製造方法
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
KR20010082251A
(ko)
*
|
1998-10-26 |
2001-08-29 |
찌바따 이찌로, 다나까 도시오 |
서방성 입자
|
US20080118556A1
(en)
*
|
1998-11-02 |
2008-05-22 |
Elan Corporation, Plc |
Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
|
US20090297597A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Gary Liversidge |
Modified Release Ticlopidine Compositions
|
NZ511442A
(en)
*
|
1998-11-02 |
2003-02-28 |
Elan Corp Plc |
Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US6270805B1
(en)
*
|
1998-11-06 |
2001-08-07 |
Andrx Pharmaceuticals, Inc. |
Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
|
AU1738800A
(en)
|
1998-11-23 |
2000-06-13 |
Bonnie Davis |
Dosage formulations for acetylcholinesterase inhibitors
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US7083808B2
(en)
*
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
IL143899A0
(en)
*
|
1998-12-24 |
2002-04-21 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition
|
DE69939553D1
(de)
|
1998-12-30 |
2008-10-23 |
Beth Israel Hospital |
Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
|
US6274162B1
(en)
|
2000-01-14 |
2001-08-14 |
Bpsi Holdings, Inc. |
Elegant film coating system
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US7250176B1
(en)
*
|
1999-04-13 |
2007-07-31 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection
|
US6878386B1
(en)
|
1999-04-13 |
2005-04-12 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
|
US6294199B1
(en)
|
1999-04-13 |
2001-09-25 |
Beecham Pharmaceuticals (Pte) Limited |
Method of treating a bacterial infection comprising administering amoxycillin
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US6410255B1
(en)
*
|
1999-05-05 |
2002-06-25 |
Aurora Biosciences Corporation |
Optical probes and assays
|
EP1591437B1
(en)
|
1999-05-14 |
2009-11-25 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
|
IE990406A1
(en)
|
1999-05-20 |
2000-12-27 |
Elan Corp Plc |
Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
|
FR2794646B1
(fr)
*
|
1999-06-09 |
2001-09-21 |
Ethypharm Lab Prod Ethiques |
Microgranules de sulfate de morphine, procede de preparation et composition les contenant
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
DK1207905T3
(da)
|
1999-09-03 |
2011-01-03 |
Brigham & Womens Hospital |
Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
|
ES2168043B1
(es)
*
|
1999-09-13 |
2003-04-01 |
Esteve Labor Dr |
Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
|
CA2383405A1
(en)
*
|
1999-09-14 |
2001-03-22 |
Smithkline Beecham Corporation |
Process for making aqueous coated beadlets
|
JP3893058B2
(ja)
*
|
1999-09-30 |
2007-03-14 |
ペンウェスト ファーマシューティカルズ カンパニー |
高度に可溶性の薬物のための徐放性マトリックス系
|
KR20130010512A
(ko)
|
1999-10-29 |
2013-01-28 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
DE60139544D1
(de)
*
|
2000-02-23 |
2009-09-24 |
Life Technologies Corp |
Veränderte, fluoreszierende proteine
|
US6663890B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Metronidazole antibiotic product, use and formulation thereof
|
AU2001239841B2
(en)
|
2000-02-24 |
2006-04-27 |
Shionogi, Inc. |
Antibiotic and antifungal compositions
|
US6627222B2
(en)
|
2000-02-24 |
2003-09-30 |
Advancis Pharmaceutical Corp. |
Amoxicillin-dicloxacillin antibiotic composition
|
US6730320B2
(en)
|
2000-02-24 |
2004-05-04 |
Advancis Pharmaceutical Corp. |
Tetracycline antibiotic product, use and formulation thereof
|
US6638532B2
(en)
|
2000-02-24 |
2003-10-28 |
Advancis Pharmaceutical Corp. |
Tetracycline—doxycycline antibiotic composition
|
US6669948B2
(en)
|
2000-02-24 |
2003-12-30 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6667057B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Levofloxacin antibiotic product, use and formulation thereof
|
US6623758B2
(en)
|
2000-02-24 |
2003-09-23 |
Advancis Pharmaceutical Corp. |
Cephalosporin-metronidazole antibiotic composition
|
US6632453B2
(en)
|
2000-02-24 |
2003-10-14 |
Advancis Pharmaceutical Corp. |
Ciprofoxacin-metronidazole antibiotic composition
|
US6663891B2
(en)
|
2000-02-24 |
2003-12-16 |
Advancis Pharmaceutical Corp. |
Erythromyacin antibiotic product, use and formulation thereof
|
US6565882B2
(en)
|
2000-02-24 |
2003-05-20 |
Advancis Pharmaceutical Corp |
Antibiotic composition with inhibitor
|
US7025989B2
(en)
*
|
2000-02-24 |
2006-04-11 |
Advancis Pharmaceutical Corp. |
Multiple-delayed released antibiotic product, use and formulation thereof
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
US6991807B2
(en)
*
|
2000-02-24 |
2006-01-31 |
Advancis Pharmaceutical, Corp. |
Antibiotic composition
|
US6610328B2
(en)
|
2000-02-24 |
2003-08-26 |
Advancis Pharmaceutical Corp. |
Amoxicillin-clarithromycin antibiotic composition
|
US6667042B2
(en)
|
2000-02-24 |
2003-12-23 |
Advancis Pharmaceutical Corp. |
Fluroquinilone antibiotic product, use and formulation thereof
|
CA2404858A1
(en)
*
|
2000-04-12 |
2001-10-25 |
Minerva Biotechnologies Corporation |
Treatment of neurodegenerative disease
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
US8012504B2
(en)
*
|
2000-04-28 |
2011-09-06 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US6372252B1
(en)
|
2000-04-28 |
2002-04-16 |
Adams Laboratories, Inc. |
Guaifenesin sustained release formulation and tablets
|
US7985420B2
(en)
*
|
2000-04-28 |
2011-07-26 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin combination drugs
|
US7838032B2
(en)
*
|
2000-04-28 |
2010-11-23 |
Reckitt Benckiser Inc. |
Sustained release of guaifenesin
|
US6955821B2
(en)
*
|
2000-04-28 |
2005-10-18 |
Adams Laboratories, Inc. |
Sustained release formulations of guaifenesin and additional drug ingredients
|
DK1296714T3
(da)
|
2000-06-22 |
2009-12-07 |
Coley Pharm Gmbh |
Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
|
DE10033023A1
(de)
*
|
2000-07-07 |
2002-01-31 |
Biogrund Gmbh |
Filmüberzugszusammensetzung auf Basis von Zellulosederivaten und Zuckeralkoholen
|
US6855721B1
(en)
|
2000-07-28 |
2005-02-15 |
Indevus Pharmaceuticals, Inc. |
Methods and compositions for alleviating stuttering
|
CA2417930A1
(en)
*
|
2000-08-10 |
2002-02-14 |
Unihart Corporation |
Pharmaceutical compositions containing lithium carbonate
|
US6756057B2
(en)
|
2000-10-12 |
2004-06-29 |
Beecham Pharmaceuticals (Pte) Limited |
Amoxicillin and potassium clavulanate dosage form
|
EP1330236A2
(en)
|
2000-10-12 |
2003-07-30 |
Beecham Pharmaceuticals (Pte) Limited |
Formulation containing amoxicillin
|
US7074417B2
(en)
*
|
2000-10-13 |
2006-07-11 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-viral product, use and formulation thereof
|
US7105174B2
(en)
*
|
2000-10-13 |
2006-09-12 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release anti-neoplastic product, use and formulation thereof
|
US7157095B2
(en)
*
|
2000-10-13 |
2007-01-02 |
Advancis Pharmaceutical Corporation |
Multiple-delayed release antifungal product, use and formulation thereof
|
US6541014B2
(en)
|
2000-10-13 |
2003-04-01 |
Advancis Pharmaceutical Corp. |
Antiviral product, use and formulation thereof
|
US6344215B1
(en)
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
KR100968128B1
(ko)
|
2000-10-30 |
2010-07-06 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US7144723B2
(en)
*
|
2000-11-16 |
2006-12-05 |
The Regents Of The University Of California |
Marine actinomycete taxon for drug and fermentation product discovery
|
JP4564714B2
(ja)
|
2000-11-27 |
2010-10-20 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
|
EP1985702A3
(en)
|
2000-12-08 |
2010-08-18 |
Coley Pharmaceutical GmbH |
CPG-like nucleic acids and methods of use thereof
|
US6706274B2
(en)
*
|
2001-01-18 |
2004-03-16 |
Scimed Life Systems, Inc. |
Differential delivery of nitric oxide
|
ITMI20010220A1
(it)
*
|
2001-02-05 |
2002-08-05 |
Valpharma Sa |
Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno
|
US20020197314A1
(en)
|
2001-02-23 |
2002-12-26 |
Rudnic Edward M. |
Anti-fungal composition
|
US20030190360A1
(en)
*
|
2001-03-13 |
2003-10-09 |
Baichwal Anand R. |
Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20030070584A1
(en)
|
2001-05-15 |
2003-04-17 |
Cynthia Gulian |
Dip coating compositions containing cellulose ethers
|
WO2002098422A1
(en)
|
2001-06-05 |
2002-12-12 |
University Of Chicago |
Use of methylnaltrexone to treat immune suppression
|
WO2003015711A2
(en)
|
2001-08-17 |
2003-02-27 |
Coley Pharmaceutical Group, Inc. |
Combination motif immune stimulatory oligonucleotides with improved activity
|
US8309118B2
(en)
|
2001-09-28 |
2012-11-13 |
Mcneil-Ppc, Inc. |
Film forming compositions containing sucralose
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
EP1455593B1
(en)
|
2001-10-06 |
2013-07-24 |
Merial Limited |
Methods and compositions for promoting growth and innate immunity in young animals
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
US6780437B2
(en)
*
|
2001-10-23 |
2004-08-24 |
Upsher-Smith Laboratories, Inc. |
Coated potassium chloride granules and tablets
|
WO2003039595A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Inex Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
US6821532B2
(en)
*
|
2001-11-16 |
2004-11-23 |
Unitel Technologies, Inc. |
Methods and compositions for the treatment of benign prostatic hypertrophy
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
KR20030056474A
(ko)
*
|
2001-12-28 |
2003-07-04 |
한국유나이티드제약 주식회사 |
카르비도파/레보도파 서방정의 조성물과 그의 제조방법
|
US20030190343A1
(en)
*
|
2002-03-05 |
2003-10-09 |
Pfizer Inc. |
Palatable pharmaceutical compositions for companion animals
|
US7022342B2
(en)
*
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
IL164354A0
(en)
|
2002-04-04 |
2005-12-18 |
Coley Pharm Gmbh |
Immunostimulatory g,u-containing oligoribonucleotides
|
CN100553625C
(zh)
|
2002-04-09 |
2009-10-28 |
弗拉梅技术公司 |
活性成分微囊的口服混悬液
|
CA2480824A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
|
US6958161B2
(en)
*
|
2002-04-12 |
2005-10-25 |
F H Faulding & Co Limited |
Modified release coated drug preparation
|
US7125563B2
(en)
*
|
2002-04-12 |
2006-10-24 |
Dava Pharmaceuticals, Inc. |
Sustained release pharmaceutical preparations and methods for producing the same
|
AU2003232078A1
(en)
|
2002-05-06 |
2003-11-17 |
Massachusetts Institute Of Technology |
Diffusion-controlled dosage form and method of fabrication including three dimensional printing
|
HUE039881T2
(hu)
|
2002-05-09 |
2019-02-28 |
Brigham & Womens Hospital Inc |
1L1RL-1, mint egy kardiovaszkuláris betegség-marker
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
US7176232B2
(en)
*
|
2002-06-24 |
2007-02-13 |
The Regents Of The University Of California |
Salinosporamides and methods for use thereof
|
MXPA05000224A
(es)
*
|
2002-06-26 |
2005-06-03 |
Alza Corp |
Piston de volumen eficiente, minimamente deformable, para sistemas de suministro osmotico de farmacos.
|
MXPA05000186A
(es)
*
|
2002-07-03 |
2005-08-17 |
Pericor Science Inc |
Composiciones de acido hialuronico y metodos de uso.
|
US20050226926A1
(en)
|
2002-07-25 |
2005-10-13 |
Pfizer Inc |
Sustained-release tablet composition of pramipexole
|
AR040682A1
(es)
*
|
2002-07-25 |
2005-04-13 |
Pharmacia Corp |
Forma de dosificacion una vez al dia de pramipexol
|
US7429619B2
(en)
|
2002-08-02 |
2008-09-30 |
Mcneil Consumer Healthcare |
Polyacrylic film forming compositions
|
US7985422B2
(en)
*
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
US20040029959A1
(en)
*
|
2002-08-08 |
2004-02-12 |
John Devane |
Isosorbide mononitrate compositions and methods of their use
|
US7160913B2
(en)
*
|
2002-09-13 |
2007-01-09 |
Thomas Jefferson University |
Methods and kit for treating Parkinson's disease
|
CA2498798A1
(en)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Sustained-release opioid formulations and methods of use
|
US7112581B2
(en)
*
|
2002-09-27 |
2006-09-26 |
Nereus Pharmaceuticals, Inc. |
Macrocyclic lactams
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
US20030049698A1
(en)
*
|
2002-10-08 |
2003-03-13 |
Wang Timothy C. |
Diagnosis and treatment of gastrointestinal disease
|
TWI319713B
(en)
*
|
2002-10-25 |
2010-01-21 |
|
Sustained-release tramadol formulations with 24-hour efficacy
|
US8487002B2
(en)
*
|
2002-10-25 |
2013-07-16 |
Paladin Labs Inc. |
Controlled-release compositions
|
JP2006515277A
(ja)
|
2002-10-29 |
2006-05-25 |
コーリー ファーマシューティカル グループ, リミテッド |
C型肝炎ウィルス感染の処置および予防に関する方法および製品
|
EP2363410B1
(en)
|
2002-11-27 |
2017-10-11 |
Minerva Biotechnologies Corporation |
Isoforms of MUC1
|
US9107804B2
(en)
*
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
PT1572217E
(pt)
*
|
2002-12-12 |
2008-11-28 |
Nycomed Gmbh |
Medicamento combinado de r,r-formoterol e ciclesonida
|
US20040114368A1
(en)
*
|
2002-12-13 |
2004-06-17 |
Shyu Shing Jy |
Light device having rotatable or movable view
|
CL2003002653A1
(es)
*
|
2002-12-18 |
2005-04-22 |
Wyeth Corp |
Composicion farmaceutica que comprende (a) un antiinflamatorio no esteroidal (nsaid), preferentemente ibuprofeno, (b) un descongestionante, preferentemente pseudoefedrina y (c) un antihistaminico, preferentemente clorfeniramina; metodo para su prepar
|
CA2510465A1
(en)
*
|
2002-12-18 |
2004-07-08 |
Pain Therapeutics |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US20040253311A1
(en)
*
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US20070218139A1
(en)
*
|
2002-12-20 |
2007-09-20 |
Smith Thomas J |
High Pressure Compaction For Pharmaceutical Formulations
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
CN101444621B
(zh)
|
2003-02-11 |
2013-11-20 |
夏尔人类遗传性治疗公司 |
使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
|
WO2004078943A2
(en)
*
|
2003-03-04 |
2004-09-16 |
California Institute Of Technology |
Alternative heterocycles for dna recognition
|
DE10311585A1
(de)
*
|
2003-03-14 |
2004-09-23 |
Basf Ag |
Wirkstoffhaltige Adsorbate
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
SI1615646T2
(sl)
|
2003-04-08 |
2022-11-30 |
Progenics Pharmaceuticals, Inc. |
Farmacevtske formulacije vsebujoče metilnatrekson
|
ITMI20030827A1
(it)
*
|
2003-04-18 |
2004-10-19 |
Unihart Corp |
Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
|
US20040241252A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Abney Christopher Charles |
Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
|
EP1651207A4
(en)
|
2003-06-12 |
2008-10-01 |
Univ Colorado |
SYSTEMS AND METHOD FOR THE TREATMENT OF INFLAMMATORY AND PROLIFERATIVE DISEASES AND WOUNDS OF HUMANS WITH FATTY ACID SUBSTANCE CHEMICALS AND / OR GLYCOLYTIC INHIBITORS
|
BRPI0411677A
(pt)
*
|
2003-06-20 |
2006-08-29 |
Nereus Pharmaceuticals Inc |
métodos de uso de compostos heterocìclicos [3.2.0] e seus análogos
|
CN1823070A
(zh)
*
|
2003-06-20 |
2006-08-23 |
加利福尼亚大学董事会 |
盐孢菌酰胺及其使用方法
|
EP2112920B1
(en)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
US7632521B2
(en)
*
|
2003-07-15 |
2009-12-15 |
Eurand, Inc. |
Controlled release potassium chloride tablets
|
AU2004258953B2
(en)
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
EP1648418A4
(en)
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
|
JP2006528189A
(ja)
|
2003-07-21 |
2006-12-14 |
アドバンシス ファーマスーティカル コーポレイション |
抗生物質産物、その使用法および製剤
|
CA2445420A1
(en)
|
2003-07-29 |
2005-01-29 |
Invitrogen Corporation |
Kinase and phosphatase assays
|
US7727752B2
(en)
|
2003-07-29 |
2010-06-01 |
Life Technologies Corporation |
Kinase and phosphatase assays
|
US7619059B2
(en)
|
2003-07-29 |
2009-11-17 |
Life Technologies Corporation |
Bimolecular optical probes
|
CA2535177A1
(en)
|
2003-08-11 |
2005-02-24 |
Advancis Pharmaceutical Corporation |
Robust pellet
|
US8062672B2
(en)
|
2003-08-12 |
2011-11-22 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
WO2005016317A1
(en)
*
|
2003-08-19 |
2005-02-24 |
Themis Laboratories Private Limited |
Process for manufacture of extended release pellets containing diltiazem hci
|
US20060173171A1
(en)
*
|
2003-08-26 |
2006-08-03 |
Bamdad Cynthia C |
Techniques and compositions for diagnosis and treatment of cancer (muci)
|
AU2004270170B2
(en)
*
|
2003-08-29 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
EP1663169A4
(en)
|
2003-09-15 |
2010-11-24 |
Middlebrook Pharmaceuticals In |
ANTIBIOTICS, ITS USE AND FORMULATION
|
EP1670482B2
(en)
*
|
2003-09-16 |
2022-06-29 |
Covis Pharma B.V. |
Use of ciclesonide for the treatment of respiratory diseases
|
EP1663156A2
(en)
*
|
2003-09-19 |
2006-06-07 |
Penwest Pharmaceuticals Company |
Chronotherapeutic dosage forms
|
NZ545921A
(en)
*
|
2003-09-19 |
2009-09-25 |
Penwest Pharmaceuticals Co |
Delayed released dosage forms
|
US20060172006A1
(en)
*
|
2003-10-10 |
2006-08-03 |
Vincent Lenaerts |
Sustained-release tramadol formulations with 24-hour clinical efficacy
|
AU2004280143A1
(en)
*
|
2003-10-11 |
2005-04-21 |
Tekmira Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
US20050095299A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Wynn David W. |
Controlled release analgesic suspensions
|
US20050095288A1
(en)
*
|
2003-11-03 |
2005-05-05 |
Andrx Labs, Llc |
Decongestant and expectorant tablets
|
US20070292498A1
(en)
*
|
2003-11-05 |
2007-12-20 |
Warren Hall |
Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
|
US20050244517A1
(en)
*
|
2003-11-05 |
2005-11-03 |
Santarus, Inc. |
Combination of proton pump inhibitor and sleep aid
|
US7387793B2
(en)
|
2003-11-14 |
2008-06-17 |
Eurand, Inc. |
Modified release dosage forms of skeletal muscle relaxants
|
US20050143350A1
(en)
*
|
2003-11-19 |
2005-06-30 |
Seed John C. |
Combination drug therapy to treat obesity
|
WO2005060610A2
(en)
*
|
2003-12-11 |
2005-07-07 |
The Trustees Of Columbia University In The City Ofnew York |
Nano-sized particles, processes of making, compositions and uses thereof
|
US20050281875A1
(en)
*
|
2003-12-17 |
2005-12-22 |
Sovereign Pharmaceuticals, Ltd. |
Promethazine containing dosage form
|
US9492541B2
(en)
*
|
2004-09-14 |
2016-11-15 |
Sovereign Pharmaceuticals, Llc |
Phenylepherine containing dosage form
|
US20050232986A1
(en)
*
|
2003-12-17 |
2005-10-20 |
David Brown |
Dosage form containing promethazine and another drug
|
US20050266032A1
(en)
*
|
2003-12-17 |
2005-12-01 |
Sovereign Pharmaceuticals, Ltd. |
Dosage form containing multiple drugs
|
EP2248895B8
(en)
|
2003-12-19 |
2016-09-21 |
Autotelic LLC |
Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
|
US7452730B2
(en)
*
|
2004-01-16 |
2008-11-18 |
California Institute Of Technology |
DNA-binding polymers
|
ATE509018T1
(de)
*
|
2004-01-23 |
2011-05-15 |
Nereus Pharmaceuticals Inc |
Als antimikrobielle mittel geeignete bisindolpyrrole
|
JP2007524698A
(ja)
*
|
2004-02-27 |
2007-08-30 |
アルタナ ファルマ アクチエンゲゼルシャフト |
シクレソニドとグリコピロニウムとの組合せ物
|
EP1722823A2
(en)
*
|
2004-02-27 |
2006-11-22 |
Antisense Pharma GmbH |
Pharmaceutical composition
|
EP1568383A3
(en)
|
2004-02-27 |
2005-11-16 |
Antisense Pharma GmbH |
Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US20050220873A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
|
CA2567249A1
(en)
*
|
2004-04-19 |
2006-10-05 |
Jds Pharmaceuticals, Llc |
Lithium combinations, and uses related thereto
|
JP2007533706A
(ja)
*
|
2004-04-20 |
2007-11-22 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
喫煙患者における呼吸器疾患の治療のためのシクレソニドの使用
|
PT1745075E
(pt)
|
2004-04-21 |
2013-06-17 |
Brigham & Womens Hospital |
Péptidos de ligação a poli-n-acetilglucosamina (pnag/dpnag) e métodos da sua utilização
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
WO2005105073A1
(en)
|
2004-04-27 |
2005-11-10 |
Medicinova, Inc. |
Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
|
US7579371B2
(en)
|
2004-04-30 |
2009-08-25 |
Nereus Pharmaceuticals, Inc. |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof
|
AU2005283141B2
(en)
|
2004-04-30 |
2012-05-10 |
Nereus Pharmaceuticals, Inc. |
(3.2.0) heterocyclic compounds and methods of using the same
|
JP4277904B2
(ja)
*
|
2004-04-30 |
2009-06-10 |
アステラス製薬株式会社 |
経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
|
AU2005244401B2
(en)
*
|
2004-05-14 |
2009-01-22 |
Green Cross Corp. |
Neuroprotective properties of dextrorotatory morphinans
|
WO2005121070A1
(en)
*
|
2004-06-04 |
2005-12-22 |
Xenoport, Inc. |
Levodopa prodrugs, and compositions and uses thereof
|
CN101023056B
(zh)
*
|
2004-06-04 |
2011-05-25 |
克塞诺波特公司 |
左旋多巴前药、和组合物及其应用
|
WO2006009602A2
(en)
|
2004-06-16 |
2006-01-26 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
US9308164B2
(en)
|
2004-06-30 |
2016-04-12 |
Sovereign Pharmaceuticals, Llc |
Hyoscyamine dosage form
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
JP2008505124A
(ja)
|
2004-07-02 |
2008-02-21 |
アドバンシス ファーマスーティカル コーポレイション |
パルス送達用錠剤
|
US20070003622A1
(en)
*
|
2004-12-16 |
2007-01-04 |
Sovereign Pharmaceuticals, Ltd. |
Diphenhydramine containing dosage form
|
US9592197B2
(en)
*
|
2004-12-16 |
2017-03-14 |
Sovereign Pharmaceuticals, Llc |
Dosage form containing diphenhydramine and another drug
|
NZ553561A
(en)
*
|
2004-08-13 |
2010-12-24 |
Boehringer Ingelheim Int |
Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
NZ553645A
(en)
*
|
2004-08-13 |
2010-09-30 |
Boehringer Ingelheim Int |
Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
|
US10624858B2
(en)
*
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
WO2006028967A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Yale University |
Regulation of oncogenes by micrornas
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US20080064680A1
(en)
*
|
2004-09-14 |
2008-03-13 |
Bamdad Cynthia C |
Methods for Diagnosis and Treatment of Cancer
|
US20060062811A1
(en)
*
|
2004-09-21 |
2006-03-23 |
Szymczak Christopher E |
Medicinal cooling emulsions
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
US20060105039A1
(en)
|
2004-10-21 |
2006-05-18 |
Jin-Wang Lai |
Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
|
JP5500773B2
(ja)
|
2004-11-11 |
2014-05-21 |
ザ ジェネラル ホスピタル コーポレーション |
副甲状腺ホルモン受容体の活性化並びに幹細胞及び前駆細胞の増殖
|
WO2006060676A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Dana Farber Cancer Institute |
Compositions and methods for treating neoplastic diseases
|
WO2006063078A2
(en)
*
|
2004-12-08 |
2006-06-15 |
Elan Corporation, Plc |
Topiramate pharmaceuticals composition
|
NZ555842A
(en)
*
|
2004-12-09 |
2010-10-29 |
Celgene Corp |
Treatment of various conditions of patients with Tourette syndrome, tics, or a family history thereof sing D-threo methylphenidate free from other isomers
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
WO2006087394A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
CA2600350C
(en)
*
|
2005-03-07 |
2015-02-10 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8524731B2
(en)
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
EP2527365A3
(en)
|
2005-03-30 |
2013-02-20 |
Minerva Biotechnologies Corporation |
Proliferation of MUC1 expressing cells
|
DK1875244T3
(en)
|
2005-03-30 |
2019-04-29 |
Minerva Biotechnologies Corp |
Proliferation of MUC1-Expressing Cells
|
WO2006110807A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
KR20070122563A
(ko)
|
2005-04-19 |
2007-12-31 |
일라이 릴리 앤드 캄파니 |
질병에의 면역학적 개입을 위한 1가 및 다가 합성 다당류항원
|
US20060241076A1
(en)
*
|
2005-04-26 |
2006-10-26 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
WO2006117400A2
(en)
|
2005-05-05 |
2006-11-09 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
|
US20060257473A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Porranee Puranajoti |
Extended release tablet
|
AR057035A1
(es)
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
AR057325A1
(es)
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
WO2007037790A2
(en)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Modified release famciclovir compositions
|
NZ565138A
(en)
|
2005-06-21 |
2012-02-24 |
Xoma Technology Ltd |
IL-1beta Binding antibodies and fragments thereof
|
US20070003621A1
(en)
*
|
2005-06-23 |
2007-01-04 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
CA2613366A1
(en)
|
2005-07-21 |
2007-02-08 |
Nereus Pharmaceuticals, Inc. |
Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
EP1957093B1
(en)
|
2005-08-29 |
2017-04-12 |
SHASHOUA, Victor E. |
Neuroprotective and neurorestorative methods and compositions
|
BRPI0615860B8
(pt)
*
|
2005-09-09 |
2021-05-25 |
Labopharm Barbados Ltd |
composição farmacêutica de liberação prolongada monolítica sólida
|
US20070098796A1
(en)
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
|
US20070098791A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
EP2883957A1
(en)
|
2005-11-25 |
2015-06-17 |
Zoetis Belgium S.A. |
Immunostimmulatory oligoribonucleotides
|
ES2812250T3
(es)
*
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
CA2631643C
(en)
*
|
2005-12-05 |
2015-07-07 |
Xenoport, Inc. |
Levodopa prodrug mesylate, compositions thereof, and uses thereof
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007090883A1
(en)
*
|
2006-02-10 |
2007-08-16 |
Boehringer Ingelheim International Gmbh |
Extended release formulation
|
US20090041844A1
(en)
*
|
2006-02-10 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Modified Release Formulation
|
US20070190141A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Aaron Dely |
Extended release opiate composition
|
CN101453993A
(zh)
|
2006-04-03 |
2009-06-10 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US20090325944A1
(en)
*
|
2006-04-12 |
2009-12-31 |
Suzanne Walker Kahne |
Methods and Compositions for Modulating Glycosylation
|
US20070253927A1
(en)
*
|
2006-04-13 |
2007-11-01 |
Gwenaelle Jegou |
Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
|
CA2649459C
(en)
*
|
2006-04-28 |
2014-07-22 |
Gruenenthal Gmbh |
Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an nsaid
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US7803778B2
(en)
|
2006-05-23 |
2010-09-28 |
Theracos, Inc. |
Glucose transport inhibitors and methods of use
|
JP5143131B2
(ja)
|
2006-05-30 |
2013-02-13 |
インターシア セラピューティクス,インコーポレイティド |
浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
|
EP2366381A1
(en)
*
|
2006-06-01 |
2011-09-21 |
MSD Consumer Care, Inc. |
Phenylephrine pharmaceutical formulations and compositions for colonic absorption
|
PE20080313A1
(es)
*
|
2006-06-01 |
2008-04-10 |
Schering Corp |
Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
|
NZ573174A
(en)
*
|
2006-06-01 |
2012-01-12 |
Msd Consumer Care Inc |
Sustained release pharmaceutical dosage form containing phenylephrine
|
BRPI0711871A2
(pt)
*
|
2006-06-01 |
2011-12-06 |
Schering Corp |
composições farmacêuticas para liberação sustentada de fenilefrina
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
US7893053B2
(en)
|
2006-06-16 |
2011-02-22 |
Theracos, Inc. |
Treating psychological conditions using muscarinic receptor M1 antagonists
|
AU2007263281B2
(en)
|
2006-06-20 |
2012-12-06 |
Transgene S.A. |
Recombinant viral vaccine
|
US20080131492A1
(en)
*
|
2006-06-23 |
2008-06-05 |
Spherics, Inc. |
Dosage forms for movement disorder treatment
|
US7682356B2
(en)
|
2006-08-09 |
2010-03-23 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies for use therein
|
US9744137B2
(en)
*
|
2006-08-31 |
2017-08-29 |
Supernus Pharmaceuticals, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
US20080057122A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Aaipharma Inc. |
Acetaminophen pharmaceutical compositions
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
WO2008147426A2
(en)
*
|
2006-10-04 |
2008-12-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for immunomodulation
|
ES2524556T3
(es)
|
2006-10-09 |
2014-12-10 |
Charleston Laboratories, Inc. |
Composiciones farmacéuticas
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
US20090297626A1
(en)
*
|
2006-11-03 |
2009-12-03 |
The Trustees Of Columbia University In The City Of New York |
Methods for preparing metal oxides
|
CA2618240C
(en)
|
2006-11-17 |
2015-01-20 |
Supernus Pharmaceuticals, Inc. |
Sustained-release formulations of topiramate
|
US8394415B2
(en)
*
|
2006-11-21 |
2013-03-12 |
Mcneil-Ppc, Inc |
Modified release analgesic suspensions
|
NZ577814A
(en)
|
2006-11-27 |
2012-03-30 |
Lundbeck & Co As H |
Imidazo[1,2-a]pyridine amide derivatives
|
BRPI0717721A2
(pt)
*
|
2006-11-28 |
2013-10-29 |
Marinus Pharmaceuticals |
"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
|
EP2094306A2
(en)
|
2006-12-20 |
2009-09-02 |
XOMA Technology Ltd. |
Treatment of il-1-beta related diseases
|
WO2008076458A1
(en)
|
2006-12-21 |
2008-06-26 |
Xenoport, Inc. |
Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
|
WO2008079387A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Xenoport, Inc. |
Catechol protected levodopa diester prodrugs, compositions, and methods of use
|
WO2008079868A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Drugtech Corporation |
Clonidine composition and method of use
|
US20100316712A1
(en)
*
|
2006-12-22 |
2010-12-16 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
US20100172882A1
(en)
*
|
2007-01-11 |
2010-07-08 |
Glazer Peter M |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
WO2008094877A2
(en)
*
|
2007-01-30 |
2008-08-07 |
Drugtech Corporation |
Compositions for oral delivery of pharmaceuticals
|
US20080187579A1
(en)
*
|
2007-02-01 |
2008-08-07 |
Pavan Bhat |
Extended-release dosage form
|
WO2008095195A2
(en)
*
|
2007-02-02 |
2008-08-07 |
Nereus Pharmaceuticals, Inc. |
Lyophilized formulations of salinosporamide a
|
US8679541B2
(en)
*
|
2007-03-14 |
2014-03-25 |
Particle Dynamics International, Llc |
Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
|
WO2008116216A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for inhibiting cancer metastasis
|
EP2137191B8
(en)
|
2007-03-29 |
2016-06-08 |
Progenics Pharmaceuticals, Inc. |
Peripheral opioid receptor antagonists and uses thereof
|
BRPI0809579B8
(pt)
|
2007-03-29 |
2021-05-25 |
Progenics Pharm Inc |
formas cristalinas e seus usos
|
DK2565195T3
(en)
|
2007-03-29 |
2015-06-29 |
Wyeth Llc |
PERIPHERAL OPIOID RECEPTOR AND ANTAGONISTS AND USES THEREOF
|
AU2008232419B2
(en)
|
2007-04-02 |
2013-06-20 |
Theracos, Inc. |
Benzylic glycoside derivatives and methods of use
|
JP2010523554A
(ja)
|
2007-04-04 |
2010-07-15 |
シグモイド・ファーマ・リミテッド |
タクロリムスの医薬組成物
|
EP2644205B1
(en)
|
2007-04-12 |
2018-06-13 |
The Brigham and Women's Hospital, Inc. |
Targeting ABCB5 for cancer therapy
|
WO2008130619A2
(en)
*
|
2007-04-20 |
2008-10-30 |
Trustees Of Boston College |
A composition comprising an inhibitor of pde4 and/or pde7
|
CN104000779A
(zh)
|
2007-04-23 |
2014-08-27 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
EP2061587A1
(en)
|
2007-04-26 |
2009-05-27 |
Sigmoid Pharma Limited |
Manufacture of multiple minicapsules
|
WO2008137747A1
(en)
|
2007-05-02 |
2008-11-13 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
AU2008252577A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Class A oligonucleotides with immunostimulatory potency
|
EP2164472A1
(en)
*
|
2007-06-01 |
2010-03-24 |
Schering-Plough Healthcare Products, Inc. |
Pharmaceutical composition comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
|
MX2009013384A
(es)
*
|
2007-06-08 |
2010-01-25 |
Addrenex Pharmaceuticals Inc |
Formulacion de liberacion extendida, y metodo para tratar disregulacion adrenergica.
|
US20100172991A1
(en)
*
|
2007-06-08 |
2010-07-08 |
Henry Joseph Horacek |
Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
|
KR101017862B1
(ko)
*
|
2007-06-08 |
2011-03-04 |
베링거 인겔하임 인터내셔날 게엠베하 |
네비라핀의 서방성 제형
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
US8524444B2
(en)
*
|
2007-06-15 |
2013-09-03 |
President And Fellows Of Harvard College |
Methods and compositions for detections and modulating O-glycosylation
|
WO2009002456A2
(en)
*
|
2007-06-21 |
2008-12-31 |
Massachusetts Institute Of Technology |
Methods and compositions relating to progenitor cells
|
US20090017167A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Herbalife International Inc. |
Mixture and beverage made therefrom for protecting cellular hydration
|
JP2010536335A
(ja)
|
2007-08-13 |
2010-12-02 |
ファイザー・インク |
活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド
|
BRPI0815708B8
(pt)
|
2007-08-23 |
2021-05-25 |
Theracos Sub Llc |
composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição
|
KR20170097787A
(ko)
|
2007-10-12 |
2017-08-28 |
다케다 파마슈티칼스 유에스에이, 인코포레이티드 |
음식 섭취와 관계없이 위장 장애를 치료하는 방법
|
KR20100069685A
(ko)
*
|
2007-10-16 |
2010-06-24 |
라보팜 인코포레이트 |
아세트아미노펜과 트라마돌의 지속 방출을 위한 이중층 조성물
|
PE20091084A1
(es)
*
|
2007-12-07 |
2009-07-23 |
Schering Plough Healthcare |
Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
|
US8394816B2
(en)
*
|
2007-12-07 |
2013-03-12 |
Irene Ghobrial |
Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
|
US8486448B2
(en)
|
2007-12-17 |
2013-07-16 |
Paladin Labs Inc. |
Misuse preventative, controlled release formulation
|
PL2391650T3
(pl)
|
2007-12-20 |
2015-03-31 |
Xoma Us Llc |
Sposoby leczenia dny
|
US20090202633A1
(en)
*
|
2008-01-03 |
2009-08-13 |
Siva Ramakrishna Velaga |
Extended release formulations of guaifenesin
|
EP3090743A1
(en)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions for treating headache and eliminating nausea
|
AU2008349873B2
(en)
|
2008-02-06 |
2014-02-13 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
AU2009222056A1
(en)
*
|
2008-03-01 |
2009-09-11 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using SPARC specific miRNAs
|
AU2009225434B2
(en)
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
JP2011522515A
(ja)
|
2008-04-10 |
2011-08-04 |
マサチューセッツ インスティテュート オブ テクノロジー |
癌幹細胞を標的とする薬剤を同定する方法およびその使用
|
US20100227853A1
(en)
*
|
2008-04-18 |
2010-09-09 |
Trustees Of Boston College |
Inhibitors of cyclic amp phosphodiesterases
|
AU2009239655B2
(en)
|
2008-04-25 |
2014-05-22 |
Innate Pharma |
Improved TLR3 agonist compositions
|
WO2009137660A2
(en)
*
|
2008-05-07 |
2009-11-12 |
Abraxis Bioscience, Llc |
Enhancement of drug therapy by mirna
|
US8524772B2
(en)
*
|
2008-05-09 |
2013-09-03 |
Tiara Pharmaceuticals, Inc. |
Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
|
CN102089312A
(zh)
*
|
2008-05-12 |
2011-06-08 |
尼瑞斯药品公司 |
作为蛋白酶体抑制剂的Salinosporamide衍生物
|
EP2303888B1
(en)
|
2008-06-12 |
2015-05-06 |
President and Fellows of Harvard College |
Compounds for antimicrobial intervention
|
CN102149280B
(zh)
|
2008-07-15 |
2017-05-24 |
泰拉科斯有限公司 |
氘化苄基苯衍生物及其使用方法
|
WO2010011347A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
US9161911B2
(en)
|
2008-08-15 |
2015-10-20 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for treatment and prevention of CNS disorders
|
DK2324002T3
(en)
|
2008-08-22 |
2016-12-19 |
Theracos Sub Llc |
Methods of making of sglt2 inhibitors
|
US20110092493A1
(en)
*
|
2008-09-24 |
2011-04-21 |
Clark Levi |
Dose-controlled transdermal promethazine compositions and methods of use
|
US20100092526A1
(en)
*
|
2008-09-26 |
2010-04-15 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
EP2346494A2
(en)
*
|
2008-09-29 |
2011-07-27 |
Wockhardt Limited |
Extended release dosage form of ropinirole
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
KR20200133324A
(ko)
|
2008-10-09 |
2020-11-27 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
WO2010047775A2
(en)
*
|
2008-10-20 |
2010-04-29 |
Xenoport, Inc. |
Methods of synthesizing a levodopa ester prodrug
|
US8399513B2
(en)
*
|
2008-10-20 |
2013-03-19 |
Xenoport, Inc. |
Levodopa prodrug mesylate hydrate
|
EP3734281A3
(en)
|
2008-11-14 |
2021-01-27 |
The Brigham and Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
US9974844B2
(en)
|
2008-11-17 |
2018-05-22 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
WO2010057870A1
(en)
|
2008-11-18 |
2010-05-27 |
Ucb Pharma, S.A. |
Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative
|
CN102264743B
(zh)
|
2008-11-25 |
2015-02-11 |
罗彻斯特大学 |
Mlk抑制剂及其使用方法
|
CN102316857A
(zh)
|
2008-12-16 |
2012-01-11 |
莱博法姆公司 |
防止误用的控释配方
|
EP2403539A2
(en)
|
2009-03-02 |
2012-01-11 |
Massachusetts Institute of Technology |
Methods and systems for treatment and/or diagnosis
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
EP2424363A1
(en)
*
|
2009-05-01 |
2012-03-07 |
Atley Pharmaceuticals, Inc. |
Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
|
EP2424534A2
(en)
*
|
2009-05-01 |
2012-03-07 |
Atley Pharmaceuticals, Inc. |
Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
|
ES2550181T3
(es)
|
2009-05-14 |
2015-11-05 |
Bayer Intellectual Property Gmbh |
Respuesta inmunitaria reforzada en especies aviares
|
DK2471518T3
(en)
|
2009-05-18 |
2017-12-04 |
Sigmoid Pharma Ltd |
COMPOSITION INCLUDING OIL DROPS
|
US8957075B2
(en)
|
2009-06-01 |
2015-02-17 |
President And Fellows Of Harvard College |
O-GlcNAc transferase inhibitors and uses thereof
|
EP2442827B1
(en)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Nanoemulsion vaccines
|
EP2451274B1
(en)
|
2009-07-08 |
2017-10-04 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
WO2011011092A1
(en)
|
2009-07-22 |
2011-01-27 |
University Of Massachusetts |
Methods and compositions to reduce oxidative stress
|
AU2010277554B2
(en)
|
2009-07-30 |
2015-02-19 |
Antisense Pharma Gmbh |
Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
|
EP2464341B1
(en)
|
2009-08-12 |
2022-07-06 |
Sublimity Therapeutics Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
EP2287304A1
(en)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
|
RU2016108987A
(ru)
|
2009-08-18 |
2018-11-26 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
PT2467377T
(pt)
|
2009-08-18 |
2017-04-04 |
Array Biopharma Inc |
Benzoazepinas substituídas como moduladores de recetores de tipo toll
|
KR20150006083A
(ko)
|
2009-09-28 |
2015-01-15 |
인타르시아 세라퓨틱스 인코포레이티드 |
실질 항정상태 약물 전달의 신속 확립 및/또는 종결
|
ES2565644T3
(es)
|
2009-11-09 |
2016-04-06 |
Xenoport, Inc. |
Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
|
CN102958515A
(zh)
|
2009-12-02 |
2013-03-06 |
阿普塔利斯制药有限公司 |
非索非那定微胶囊及含有非索非那定微胶囊的组合物
|
WO2011133803A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
WO2011133802A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
WO2011140173A1
(en)
|
2010-05-04 |
2011-11-10 |
The Brigham And Women's Hospital, Inc. |
Detection and treatment of fibrosis
|
MX2012012991A
(es)
|
2010-05-11 |
2012-11-30 |
Cima Labs Inc |
Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
|
CN103153994B
(zh)
|
2010-05-24 |
2016-02-10 |
罗切斯特大学 |
双环杂芳基激酶抑制剂及使用方法
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
US8623409B1
(en)
|
2010-10-20 |
2014-01-07 |
Tris Pharma Inc. |
Clonidine formulation
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
KR101940826B1
(ko)
|
2010-12-22 |
2019-01-21 |
바이엘 인텔렉쳐 프로퍼티 게엠베하 |
소종 동물에서의 증대된 면역 반응
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
PT2663555T
(pt)
|
2011-01-12 |
2017-03-23 |
Array Biopharma Inc |
Benzoazepinas substituídas como moduladores de recetores tipo-toll
|
AU2012205486B2
(en)
|
2011-01-12 |
2017-02-02 |
Array Biopharma, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
CN103459598B
(zh)
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
Mir-124的合成模拟物
|
MY165507A
(en)
|
2011-02-03 |
2018-03-28 |
Mirna Therapeutics Inc |
Synthetic mimics of mir-34
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
JP6133790B2
(ja)
|
2011-02-18 |
2017-05-24 |
ザ スクリプス リサーチ インスティテュート |
ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化
|
BR112013027057A2
(pt)
|
2011-04-21 |
2020-08-11 |
Trustees Of Tufts College |
composições e métodos para a estabilização de agentes ativos
|
ES2583877T3
(es)
|
2011-06-01 |
2016-09-22 |
Janus Biotherapeutics, Inc. |
Moduladores novedosos del sistema inmunitario
|
CN109912602A
(zh)
|
2011-06-01 |
2019-06-21 |
贾纳斯生物治疗有限公司 |
新型免疫系统调节剂
|
US8524664B2
(en)
|
2011-06-02 |
2013-09-03 |
Colorado Seminary, Which owns and Operates The Univeristy of Denver |
Methods of treating overproduction of cortisol using ACTH antagonist peptides
|
SG10201608671SA
(en)
|
2011-07-18 |
2016-12-29 |
Harvard College |
Engineered Microbe-Targeting Molecules and Uses Thereof
|
WO2013013061A1
(en)
|
2011-07-19 |
2013-01-24 |
University Of Vermont And State Agricultural College |
Methods and compounds for treating cancer
|
WO2013020044A1
(en)
|
2011-08-03 |
2013-02-07 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Treatment of fibrosis using microrna-19b
|
US9873694B2
(en)
|
2011-10-04 |
2018-01-23 |
Janus Biotherapeutics, Inc. |
Imidazole quinoline-based immune system modulators
|
US9173884B2
(en)
|
2011-11-30 |
2015-11-03 |
Trustees Of Boston College |
Inhibitors of phosphodiesterase 11 (PDE11)
|
US8962687B2
(en)
|
2012-12-05 |
2015-02-24 |
Medicinova, Inc. |
Method of treating liver disorders
|
JP2013119550A
(ja)
|
2011-12-08 |
2013-06-17 |
Medicinova Inc |
非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
|
JP6320300B2
(ja)
|
2011-12-19 |
2018-05-09 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
座瘡を治療するための方法
|
JP2015509091A
(ja)
|
2012-01-09 |
2015-03-26 |
ザ スクリプス リサーチ インスティテュート |
ヒト化抗体
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
EP3936144A1
(en)
|
2012-07-11 |
2022-01-12 |
The University of Vermont and State Agriculture College |
Methods and compositions for metabolic regulation
|
RU2677639C2
(ru)
|
2012-07-13 |
2019-01-18 |
Шин Ниппон Биомедикал Лэбораториз, Лтд. |
Хиральный адъювант нуклеиновой кислоты
|
US8962020B2
(en)
*
|
2012-07-26 |
2015-02-24 |
Glycadia Inc. |
Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid
|
US9636376B2
(en)
*
|
2012-09-11 |
2017-05-02 |
Innopharma, Inc. |
Stable compositions of peptide epoxy ketones
|
EP2904119B1
(en)
|
2012-10-02 |
2020-06-17 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
WO2014055941A2
(en)
|
2012-10-04 |
2014-04-10 |
Pappalardo Juan Sabastian |
Compounds and methods for targeted immune system delivery
|
WO2014074805A1
(en)
|
2012-11-08 |
2014-05-15 |
Whitehead Institute For Biomedical Research |
Selective targeting of cancer stem cells
|
WO2014085795A1
(en)
|
2012-11-30 |
2014-06-05 |
University Of Rochester |
Mixed lineage kinase inhibitors for hiv/aids therapies
|
US9750718B2
(en)
|
2012-12-12 |
2017-09-05 |
The Charlotte-Mecklenburg Hospital Authority |
Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
|
US9872851B2
(en)
|
2012-12-12 |
2018-01-23 |
The Charlotte-Mecklenburg Hospital Authority |
Methods of treating portal hypertension
|
EP4180448A1
(en)
|
2013-03-15 |
2023-05-17 |
Trustees of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
JP6230691B2
(ja)
|
2013-03-21 |
2017-11-15 |
ユープラシア ファーマシューティカルズ ユーエスエー エルエルシーEupraxia Pharmaceuticals Usa Llc |
関節の炎症およびそれに関連する疼痛を治療するための注射用持続放出組成物およびその使用方法
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
KR102352728B1
(ko)
|
2013-07-25 |
2022-01-18 |
메디시노바, 인크. |
트리글리세라이드, 총 콜레스테롤, 및 저밀도 지단백질의 혈중농도를 감소시키는 방법
|
KR102302634B1
(ko)
|
2013-09-13 |
2021-09-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제 및 이의 조성물
|
WO2015057834A1
(en)
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
CN105814083A
(zh)
|
2013-10-15 |
2016-07-27 |
加州生物医学研究所 |
嵌合抗原受体t细胞开关和其用途
|
US10208102B2
(en)
|
2013-11-01 |
2019-02-19 |
University Of Oslo |
Albumin variants and uses thereof
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
EP3546474B1
(en)
|
2013-12-18 |
2021-07-07 |
President and Fellows of Harvard College |
Crp capture/detection of gram positive bacteria
|
NZ721908A
(en)
|
2013-12-20 |
2022-12-23 |
Massachusetts Gen Hospital |
Combination therapy with neoantigen vaccine
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
WO2015108046A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
EP3095459A4
(en)
|
2014-01-15 |
2017-08-23 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
JP6772065B2
(ja)
|
2014-02-28 |
2020-10-21 |
バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Animal Health Gmbh |
免疫賦活プラスミド
|
US10398672B2
(en)
|
2014-04-29 |
2019-09-03 |
Whitehead Institute For Biomedical Research |
Methods and compositions for targeting cancer stem cells
|
WO2015170195A1
(en)
*
|
2014-05-03 |
2015-11-12 |
GORREPATI, Navaneeta Krishna |
Hydrazaline hydrochloride pellets and its preparation method
|
US9346754B2
(en)
|
2014-05-08 |
2016-05-24 |
Medicinova, Inc. |
Method of treating advanced non-alcoholic steatohepatitis
|
US20150321989A1
(en)
|
2014-05-08 |
2015-11-12 |
Medicinova, Inc. |
Method of treating idiopathic pulmonary fibrosis
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
EP3721875B1
(en)
|
2014-05-09 |
2023-11-08 |
Yale University |
Particles coated with hyperbranched polyglycerol and methods for their preparation
|
JP6469727B2
(ja)
|
2014-06-02 |
2019-02-13 |
メディシノバ・インコーポレイテッドMediciNova, Inc. |
線維症の抑制又は治療方法
|
CN107108629A
(zh)
|
2014-08-22 |
2017-08-29 |
贾纳斯生物治疗有限公司 |
新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法
|
EP3189007B1
(en)
|
2014-09-02 |
2019-10-02 |
Bhupinder Singh |
Deuterated or a non-deuterated molecule and pharmaceutical formulations
|
KR102487452B1
(ko)
*
|
2014-09-15 |
2023-01-10 |
오르파짐 에이/에스 |
아리모클로몰 제제
|
CA2959186C
(en)
|
2014-09-19 |
2020-03-24 |
The Procter & Gamble Company |
Pulsed release phenylephrine dosage forms
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
EP3204120B1
(en)
|
2014-10-08 |
2021-05-26 |
Pacific Northwest Research Institute |
Methods and compositions for increasing the potency of antifungal agents
|
EP3204039B1
(en)
|
2014-10-10 |
2022-06-08 |
The Regents Of The University Of Michigan |
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
|
WO2016061531A1
(en)
|
2014-10-17 |
2016-04-21 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progression
|
CA2936741C
(en)
|
2014-10-31 |
2018-11-06 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
PL3215127T3
(pl)
|
2014-11-07 |
2021-05-17 |
Sublimity Therapeutics Limited |
Kompozycje zawierające cyklosporynę
|
WO2016077832A2
(en)
|
2014-11-14 |
2016-05-19 |
Gemphire Therapeutics Inc. |
PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS
|
CA2967826C
(en)
|
2014-11-26 |
2024-01-16 |
Medicinova, Inc. |
A combination of ibudilast and riluzole and methods of using same
|
MA41152A
(fr)
*
|
2014-12-12 |
2017-10-17 |
Johnson & Johnson Consumer Inc |
Procédé de fabrication de particules de résinate de phényléphrine ; particules de résinate de phényléphrine et utilisation des particules de résinate de phényléphrine dans des formulations pharmaceutiques
|
US10993997B2
(en)
|
2014-12-19 |
2021-05-04 |
The Broad Institute, Inc. |
Methods for profiling the t cell repertoire
|
WO2016100975A1
(en)
|
2014-12-19 |
2016-06-23 |
Massachsetts Institute Ot Technology |
Molecular biomarkers for cancer immunotherapy
|
WO2016130726A1
(en)
|
2015-02-10 |
2016-08-18 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies
|
JP6944373B2
(ja)
|
2015-02-18 |
2021-10-06 |
ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジUniversity Of Vermont And State Agricultural College |
Mcjアゴニストおよびそれらに関する使用
|
EP4226937A3
(en)
|
2015-03-05 |
2023-09-27 |
Northwestern University |
Non-neuroinvasive viruses and uses thereof
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
CA3019311A1
(en)
|
2015-04-15 |
2016-10-20 |
University Of Massachusetts |
Compositions and methods for xi chromosome reactivation
|
WO2016168773A2
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
IL294183B2
(en)
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
WO2016205488A1
(en)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
JP2018521130A
(ja)
|
2015-07-10 |
2018-08-02 |
ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジUniversity Of Vermont And State Agricultural College |
薬物性疾患および状態を治療する方法および組成物
|
CN108289928A
(zh)
|
2015-08-06 |
2018-07-17 |
哈佛大学校长及研究员协会 |
改进的微生物-结合分子和其用途
|
EP3337900B1
(en)
|
2015-08-20 |
2021-04-07 |
Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE |
Methods and compositions to treat liver diseases and conditions
|
CA2998745A1
(en)
|
2015-09-17 |
2017-03-23 |
University Of Massachusetts |
Compositions and methods for modulating fmr1 expression
|
US11278506B2
(en)
|
2015-10-09 |
2022-03-22 |
Rb Health (Us) Llc |
Pharmaceutical formulation
|
MX2018005035A
(es)
|
2015-10-27 |
2018-09-06 |
Eupraxia Pharmaceuticals Inc |
Formulaciones de liberacion sostenida de anestesicos locales.
|
JP2018532808A
(ja)
*
|
2015-11-06 |
2018-11-08 |
ジェムフィアー セラピューティクス インコーポレイテッド |
心血管疾患の処置のためのゲムカベンの組み合わせ
|
AU2017221405A1
(en)
|
2016-02-16 |
2018-09-20 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
US20200308590A1
(en)
|
2016-02-16 |
2020-10-01 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
EP3416494A4
(en)
*
|
2016-02-17 |
2019-11-13 |
Corr-Jensen Inc. |
RETARD VITAMINS AND MINERAL PRODUCTS IN EDIBLE OILS
|
EP3423041A4
(en)
|
2016-03-04 |
2019-09-11 |
Charleston Laboratories, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
CN116333140A
(zh)
|
2016-04-08 |
2023-06-27 |
埃缇健康公司D/B/A泽尔拜尔 |
网蛋白-1结合抗体及其用途
|
EP3733694A1
(en)
|
2016-05-16 |
2020-11-04 |
Intarcia Therapeutics, Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
US20190322643A1
(en)
|
2016-06-29 |
2019-10-24 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
US11026908B2
(en)
*
|
2016-07-17 |
2021-06-08 |
Mapi Pharma Ltd. |
Extended release dosage forms of pregabalin
|
SG11201900710YA
(en)
|
2016-07-26 |
2019-02-27 |
Bayer Animal Health Gmbh |
Increased fertility in bovine species
|
CN109715151A
(zh)
|
2016-08-11 |
2019-05-03 |
奥维德医疗公司 |
用于治疗癫痫性紊乱的方法和组合物
|
CA3033973A1
(en)
*
|
2016-08-15 |
2018-02-22 |
Corr-Jensen Inc. |
Time release of fat-soluble actives
|
EP3529268A1
(en)
|
2016-10-19 |
2019-08-28 |
The Scripps Research Institute |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
CA3042700A1
(en)
|
2016-11-07 |
2018-05-11 |
University Of Massachusetts |
Therapeutic targets for facioscapulohumeral muscular dystrophy
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
IL307966A
(en)
|
2017-01-03 |
2023-12-01 |
Intarcia Therapeutics Inc |
Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP3576726A1
(en)
|
2017-02-06 |
2019-12-11 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
US10278930B2
(en)
|
2017-03-16 |
2019-05-07 |
The Procter & Gamble Company |
Method for relieving sinus congestion
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
US11225512B2
(en)
|
2017-04-27 |
2022-01-18 |
University Of New Hampshire |
Compositions and methods for ceramide-elevating therapeutic strategies
|
US11865093B2
(en)
|
2017-07-14 |
2024-01-09 |
University Of Massachusetts |
Methods and compositions for treating inflammation
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
EP3678699A1
(en)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Vaccine molecules
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
RU2020135495A
(ru)
|
2018-03-28 |
2022-04-29 |
Гербалайф Интернэшнл Оф Америка, Инк. |
Ацетилирование полисахаридов
|
HUE059318T2
(hu)
|
2018-04-19 |
2022-11-28 |
Tvardi Therapeutics Inc |
STAT3 inhibitorok
|
WO2020082076A1
(en)
|
2018-10-19 |
2020-04-23 |
Board Of Regents, The University Of Texas System |
Engineered long interspersed element (line) transposons and methods of use thereof
|
KR20210072013A
(ko)
*
|
2018-11-02 |
2021-06-16 |
(주)셀트리온 |
비후성 심근증 치료용 약학 조성물
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
CA3119728A1
(en)
|
2018-11-21 |
2020-05-28 |
Tremeau Pharmaceuticals, Inc. |
Purified forms of rofecoxib, methods of manufacture and use
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
EP3677693A1
(en)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimeric gene trancripts (tcgts) as cancer biomarkers
|
CN114206389A
(zh)
|
2019-03-21 |
2022-03-18 |
有丝分裂疗法有限责任公司 |
用于靶向递送治疗剂的多价配体簇
|
WO2020257779A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
WO2020257776A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
US20220280656A1
(en)
|
2019-07-31 |
2022-09-08 |
Yale University |
Compositions and methods for treating sickle cell disease
|
EP4009982A4
(en)
|
2019-08-05 |
2023-08-09 |
Marinus Pharmaceuticals, Inc. |
GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS
|
AU2020328507A1
(en)
|
2019-08-12 |
2022-03-17 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
CN115551594A
(zh)
|
2019-10-24 |
2022-12-30 |
米诺陶治疗公司 |
经细胞因子修饰的嵌合抗体及其使用方法
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
AU2020395254A1
(en)
|
2019-12-06 |
2022-06-02 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|
EP4107267A1
(en)
|
2020-02-21 |
2022-12-28 |
Mitotherapeutix LLC |
Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
|
US11918689B1
(en)
|
2020-07-28 |
2024-03-05 |
Tris Pharma Inc |
Liquid clonidine extended release composition
|
US11071739B1
(en)
|
2020-09-29 |
2021-07-27 |
Genus Lifesciences Inc. |
Oral liquid compositions including chlorpromazine
|
EP4059498A1
(en)
|
2021-03-16 |
2022-09-21 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Methods and compositions for treating conditions associated with hypermineralization
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CA3217719A1
(en)
|
2021-05-28 |
2022-12-01 |
Kazuko Matsuda |
Phenoxyalkylcarboxylic acid derivatives and their use in lowering triglyceride levels
|
WO2022261115A1
(en)
|
2021-06-07 |
2022-12-15 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2024039376A1
(en)
|
2022-08-18 |
2024-02-22 |
Elanco Us Inc. |
Method for improving growth performance in feedlot cattle
|